Wenjuan Hu
Overview
Explore the profile of Wenjuan Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang G, Huang R, Qian M, Hu W, Huang R
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006533
: Photothermal therapy has the potential to enhance the precision and safety of oncological treatments. However, applicable photothermal agents associated with its photothermal activated immunogenic cell death remain exploiting. :...
2.
3.
Hu W, Li X, Guo W, Shangguan Y, Xia J, Feng X, et al.
J Mol Diagn
. 2024 Jul;
26(9):832-842.
PMID: 38972592
Timely detection of Aspergillus infection is crucial given the high mortality rate of pulmonary aspergillosis (PA). Here, the diagnostic performances for PA of mycological culture, Aspergillus real-time PCR, and metagenomic...
4.
Guo W, Li X, Ding C, Dai X, Wu S, Shi Y, et al.
BMC Pulm Med
. 2024 Jul;
24(1):312.
PMID: 38961438
Background: The Omicron variant broke out in China at the end of 2022, causing a considerable number of severe cases and even deaths. The study aimed to identify risk factors...
5.
Guo W, Shangguan Y, Ji Z, Hu M, Li X, Hu W, et al.
J Glob Antimicrob Resist
. 2024 May;
38:83-89.
PMID: 38719186
Objectives: Mycobacterium abscessus complex (MABC) is the most common rapidly growing Mycobacterium species in structural pulmonary diseases and can be life-threatening. This study aimed to assess the clinical characteristics and...
6.
Jiang Y, Dou H, Xu B, Xu B, Zhou W, Wang H, et al.
Epidemiol Infect
. 2024 Apr;
152:e75.
PMID: 38634450
This paper retrospectively analysed the prevalence of macrolide-resistant (MRMP) in some parts of China. Between January 2013 and December 2019, we collected 4,145 respiratory samples, including pharyngeal swabs and alveolar...
7.
Li X, Wu Y, Yang Y, Wu Y, Yu X, Hu W
Free Radic Res
. 2023 Dec;
58(1):57-68.
PMID: 38145457
Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important transcriptional regulator that plays a protective role against various cardiovascular diseases. Omaveloxolone is a newly discovered potent activator of Nrf2...
8.
Yang Q, Wang X, Li H, Yin X, Liu H, Hu W, et al.
Hum Exp Toxicol
. 2023 Nov;
42:9603271231215499.
PMID: 37950702
Cyclosporine (CsA) is an immunosuppressive agent that often causes acute kidney injury (AKI) in children. The specific mechanisms underlying CsA-induced AKI are currently unknown. This study used an integrated network...
9.
Guo W, Hu M, Xu N, Shangguan Y, Xia J, Hu W, et al.
Int J Antimicrob Agents
. 2023 Jun;
62(2):106875.
PMID: 37276894
Central nervous system (CNS) tuberculosis (TB) is a devastating and often life-threatening disease caused by Mycobacterium tuberculosis. Contezolid, a new oxazolidinone, has demonstrated potent antimycobacterial activity in both in-vivo and...
10.
Shangguan Y, Guo W, Feng X, Shi Y, Li X, Pan Z, et al.
Int J Infect Dis
. 2023 Apr;
132:99-107.
PMID: 37068583
Objectives: Faropenem has antituberculosis activity in vitro but its utility in treating patients with tuberculosis (TB) is unclear. Methods: We conducted an open-label, randomized trial in China, involving newly diagnosed,...